| U.S. Steel [X] - Last Close: $22.72 U.S. Steel just received a buyout bid. On Sunday, the legendary steel company received an unsolicited buyout offer from Cleveland Cliffs [CLFS] that offered $7.3 billion of cash and stock. Cleveland Cliffs announced the offer on Sunday. The deal would pay about $35 per share of X, representing a premium of 43% compared to its last close. CC decided to go public with the offer after U.S. Steel turned it down, calling it "unreasonable," but it has announced a formal review process after receiving multiple bids. X is one of this morning's top stocks with a 28.1% gain. My Take: X is still trading well below the proposed acquisition price of $35, so the market isn't convinced this deal is going to go through. Prime Number Acquisition I Corp. [PNAC] - Last Close: $8.03 Prime Number Acquisition is heating up after an announcement. The SPAC filed a Form 425 this morning announcing a new forward purchase agreement with Meteora Capital Partners. Under the terms of the deal, Meteora has greed to purchase up to 2 million shares. Meteora also agreed to cover up to 50% of a $1 million shortfall that the SPAC needs to close its planned combination with NOCO-NOCO PTE. PNAC is up 44.5% on the news. My Take: Sounds like Meteora just saved PNAC's skin. The SPAC market is wildly unpredictable, and I don't know enough about NOCO-NOCO to make a call. Freight Technologies [FRGT] - Last Close: $0.56 A bullish business update is boosting shares of Freight Technologies. This morning, the tech-focused logistics company announced its Q2 financial results, and the numbers impressed. Freight Tech's sales grew 29% compared to last quarter, and it reported a whopping 93% YoY improvement in margins. CFO Paul Freudenthaler called it "another quarter of strong growth and improved profitability." FRGT is up 36.7% in early trading. My Take: FRGT's Q2 results are encouraging, but its chart is ugly, and the company has a long road ahead of it to get back on track. Taysha Gene Therapies [TSHA] - Last Close: $0.7390 Taysha Gene is rallying on new earnings data and an upbeat clinical update. This morning, the company reported initial clinical data from a key drug trial and better-than-expected Q2 revenues on its latest quarterly report. Taysha said initial clinical data from a REVEAL Phase 1/2 trial of TSHA-102 showed the drug was safe and produced improvements in Rett Syndrome patients. The company reported a wider-than-expected Q2 loss of $(0.38) versus the Street's $(0.31) target, but its $2.4 million sales figure topped expectations. The company also announced a $150 million private placement financing round. Shares of TSHA are up 52.9% in response to the company's flurry of early-morning announcements. My Take: TSHA appears to be up-trending after a long decline. This rally could give it the push it needs to pivot into a new trading range. GainersAGBA Acquisition [AGBA] >> +34.5%AMC Entertainment Pref. [APE] >> +25.8%Green Giant [GGE] >> +26.4%Steakholder Foods [STKH] >> +21.3%DeclinersOxbridge Acquisition [JTAI] >> (34.4%) AMC Entertainment [AMC] >> (34.1%)Pheonix Motor [PEV] >> (25.0%)Aurora Acquisition [AURC] >> (23.3%) Roivant Sciences Ltd. [ROIV] ... AM
Monday.Com Ltd. [MNDY] ... AM
Jinkosolar Holding Company Limited Dr [JKS] ... AM
Altus Power, Inc. [AMPS] ... AM
Rumble Inc. [RUM] ... PM
Getty Images Holdings, Inc. [GETY] ... PM
Definitive Healthcare Corp. [DH] ... PM
Navitas Semiconductor Corporation [NVTS] ... PM
Hesai Group Dr [HSAI] ... PM
AST Spacemobile, Inc. [ASTS] ... PM None | 